TrialCancer research communications2025

First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.

Shivaani Kummar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.